BCAT BlackRock Capital Allocation Term Trust Insider Trading

Saba Capital sells 184,539 shares (1.7% of holdings) in 2 transactions for $2,741,140.17 at BCAT

Saba Capital Management, a 10% owner of BlackRock Capital Allocation Term Trust, executed 2 separate sales on 2025-05-15 and 2025-05-16, selling 55,335 shares at $14.91 and 129,204 shares at $14.83 respectively, for a combined $2,741,140.17 at a blended average price of $14.85. The sales reduced holdings from 10,574,101 to 10,389,562 shares, representing a -1.7% reduction relative to pre-transaction holdings. The current price is $14.77, below both transaction prices. Saba's cross-ticker track record shows 17 prior buys versus only 3 prior sells, but prior sales cannot yet be evaluated for timing (none of 3 prior same-ticker trades at BCAT have reached 90-day measurement windows). This sale adds to a pattern of selling activity at BCAT over the prior three trading days (2025-05-12 through 2025-05-15), though the measurable conviction or reasoning behind the sales remains unclear without forward-looking context.

Saba Capital sells 286,819 BCAT shares (2 transactions, $4.4M) at $15.25–$15.27; continues uninterrupted sales pattern within 7 days despite 7.2% 30-day price gain.

Saba Capital Management, the 10% owner, executed 2 separate sales totaling 286,819 shares for $4,376,210.25 on May 13–14, 2025, at an average price of $15.26, reducing holdings by 2.6% to 10,574,101 shares. The sales occur at prices 2.5% above the current market price of $14.89 and continue a concentrated selling pattern: this represents the most recent in a series of 4 distinct sales at BCAT within a narrow 7-day window (May 8–15), suggesting execution of a structured disposition plan rather than sporadic decisions. Against the backdrop of a 7.2% 30-day price gain and a 52-week range of $13.20–$17.00, the timing of these sales at the mid-to-upper end of recent trading levels raises questions about Saba's forward outlook for the trust, particularly given the concentrated velocity of the sales.

Saba Capital sold 151,698 BCAT shares at $15.16 (2025-05-12); part of 5-trade sell sequence in 6 days while 10% owner

Saba Capital Management, a 10% owner of BlackRock Capital Allocation Term Trust, executed a sale of 151,698 shares at $15.16 on 2025-05-12, reducing holdings by 1.4% to 10,860,920 shares. This sale is notable because it is part of a rapid sequence of 5 consecutive sell transactions at the same ticker between 2025-05-06 and 2025-05-13, collectively reducing the position within a 6-day window. The current price of $15.27 is -10.2% from the 52-week high of $17.00, and Saba's cross-ticker track record shows 15 prior buys against only 5 prior sells, indicating a historically net-long posture; the concentrated sell activity at BCAT stands out against this pattern. As outcomes for these recent BCAT sales are not yet measurable, the sequence itself—rather than timing accuracy—warrants investor attention given the position's material size and the sustained reduction over a compressed timeframe.

Saba Capital (10% owner) sells 134,518 shares (2 transactions) at $14.81 avg, -1.2% of holdings.

Saba Capital Management sold 2 separate tranches totaling 134,518 shares on 2025-05-08 and 2025-05-09 at a blended average price of $14.81 per share, reducing its position by 1.2% from 11.15M to 11.01M shares. At the time of sale, the stock was trading near the middle of its 52-week range ($13.20–$17.00) and at -10.6% from the 52-week high. Saba's cross-ticker track record shows 15 prior buys against only 5 prior sells, suggesting a historical bias toward accumulation over distribution. Same-ticker history at BCAT shows four consecutive sell transactions in close sequence (May 5–12, 2025), all still too recent to measure 90-day outcomes; thus no timing pattern can yet be established for this position. The modest scale of the reduction (1.2% of holdings) and maintenance of substantial remaining ownership suggests incremental position management rather than conviction shift.

10% owner Saba Capital sells 149,202 shares of BCAT across 2 days for $2,196,253.44 at $14.72

Saba Capital Management, L.P., a 10% owner of BlackRock Capital Allocation Term Trust, executed 2 separate sales totaling 149,202 shares for $2,196,253.44 on 2025-05-06 and 2025-05-07. The blended average transaction price was $14.72, 0.3% below the current price of $14.76; the stock is currently -13.2% from its 52-week high of $17.00. Post-transaction, Saba retains 11,147,136 shares, representing a -1.3% reduction from pre-transaction holdings of 11,296,338 shares. Across Saba's prior trades at BCAT (3 prior discrete transactions), outcomes are not yet measurable; his cross-ticker track record spans 16 buys and 4 sells, though no prior sells at this ticker have accumulated a measurable 90-day outcome to establish a timing pattern. The narrow price decay and modest position reduction in an illiquid closed-end fund context warrants observation of follow-on filing activity.

Saba Capital Management sold 85,570 shares of BCAT at $14.78 on 2025-05-05 (Total value: $1,264,724.60), reducing holdings to 11,296,338 shares.

Saba Capital Management, a 10% owner, executed a sale of 85,570 shares representing a -0.8% reduction in its BCAT position. The transaction occurred at $14.78, with the stock currently trading at $14.67, down 13.7% from its 52-week high of $17.00 but up 7.5% over the past 30 days. Notably, this sale is part of a rapid sequence of four consecutive selling days at BCAT (2025-04-30, 2025-05-01, 2025-05-02, 2025-05-05), suggesting a deliberate liquidation pattern rather than isolated activity. Across Saba's cross-ticker open-market history, the firm has executed 15 prior buys and 5 prior sells, but outcomes on the 4 recent BCAT same-ticker sells cannot yet be measured.

Saba Capital sells 99,231 shares of BCAT for $1,467,978.98 across 2 trades (May 1-2), reducing stake by 0.9%

Saba Capital Management sold 99,231 shares of BlackRock Capital Allocation Term Trust (BCAT) in 2 separate transactions on 2025-05-01 and 2025-05-02, receiving a blended average price of $14.79. The position reduced from 11.48M to 11.38M shares, representing a 0.9% net reduction in holdings. At the time of sale, the stock was trading at $14.73 on the filing date, suggesting the transactions occurred near prevailing market levels. This sale occurs within Saba Capital's broader activity profile, which shows 17 prior buys across all tickers against only 3 prior sells, indicating a net accumulation orientation historically, though this ticker-specific context at BCAT involves prior sells as well.

Saba Capital Management sold 311,729 shares of BCAT at $14.39 on 2025-04-30 for $4,485,780.31; reduces stake to 11.48M shares.

Saba Capital Management, a 10% owner, sold 311,729 shares of BlackRock Capital Allocation Term Trust at $14.39, reducing its post-transaction holdings to 11,481,139 shares from 11,792,868 shares. This represents a 2.6% reduction in the filer's stake. The trade occurred when BCAT was trading 13.0% below its 52-week high of $17.00 and 2.8% below the current price of $14.79. Across Saba's open-market history, the track record shows 18 prior buys against only 2 prior sells, indicating a strongly accumulative bias; however, this second recent sell at BCAT (following a sale on 2025-05-01) represents a shift to liquidation activity at this specific holding. The timing context and magnitude of the position reduction warrant observation, particularly as the stock has declined 4.3% over the prior 90 days.

Saba Capital sells 150,794 shares (1.3% of position) at $15.00 average across 2 days; stock down 12.8% from 52-week high.

Saba Capital Management, L.P., a 10% owner, executed 2 separate sales totaling 150,794 shares for $2,261,647.08 on 2025-03-13 and 2025-03-14 at a blended average price of $15.00. The filing occurs while the stock is trading at $14.82, down 12.8% from its 52-week high of $17.00 and down 4.8% over the prior 30 days. Saba's post-transaction holdings of 11,818,748 shares represent a 1.3% reduction from pre-transaction levels. The sell activity follows a pattern of 5 consecutive sales at BCAT spanning 2025-03-05 through 2025-03-12, and occurs in a context where the stock has declined meaningfully from its recent peak. While Saba's cross-ticker track record shows 14 prior buys against 6 prior sells, the recent sequence of sales at this specific ticker and the depressed price environment relative to 52-week highs warrant observation of whether this reflects a directional reduction in exposure.

Saba Capital Management (10% owner) sold 68,268 shares of BCAT across two days for $1,028,954.04; now holds 11,969,542 shares post-transaction.

Saba Capital Management filed Form 4 reporting 2 separate sales totaling 68,268 shares for $1,028,954.04 at a blended average price of $15.07 on March 11–12, 2025. The stake declined 0.6% to 11,969,542 shares. This sale occurs while the stock trades 11.5% below its 52-week high and down 4.1% over the past 30 days, but the current price of $15.04 remains within the 52-week range of $15.00–$17.00. Saba's prior trades at BCAT show a pattern of five consecutive sells dating back to March 4, with no measurable outcomes yet on any of them. Across Saba's cross-ticker open-market history, 13 prior buys and 7 prior sells show a mix of activity; the timing accuracy of those historical sells cannot yet validate or contradict a pattern at this ticker.